Supplementary data 

 

Table 2. Probes in 18q used for specifying the breakpoint in translocation (12;18)(q12;q21), patient 3 

 
Markers in the BAC or YAC 

 
Genes in the probe 

piasx-beta 
MBD1 
RAB27B, part, Se57-1, LOC3427765 
TCF4, part 
 
TCF4, part 
LOC350570, LOC 284256 
LOC 284256 
LOC 284256 
LOC342769, LOC342770 
LOC342772, TNXL,WDR7, part 
WDR7, part 
WDR7, part, LOC350571 
LOC350572, LOC342773, SIAT8C, LOC342774 
SIAT8C, LOC342774, Onecut, LOC342775 
FECH, NARS, ATP8B1, part 
ATP8B1 part, LOC342776, LOC284288, 
LOC342777 part 
LOC284288, LOC342777 
 
 
MALT1 
BCL2 

a Backs in the same region as YAC 852H2 (between AFM357TD5 and AFM191XCP9) 
b LSI/IGH/BCL2 dual color, dual fusion translocation probe Vysis®, Vysis Inc., Downers Grove, Illnois, USA 

 
 

Band 
 
18q12.3 
18q21 
18q21 
18q21.1 
18q21 
18q21 
18q21 
18q21 
18q21.2 
18q21 
18q21 
18q21 
18q21 
18q21 
18q21 
18q21 
18q21 

18q21 
18q21 
18q21 
18q21 
18q21.3 
 

  

YAC or BAC 

RP11- 
RP11- 
RP11- 
RP11- 
852H2 
RP11- 
RP11- 
RP11- 
RP11- 
RP11- 
RP11- 
RP11- 
RP11- 
RP11- 
RP11- 
RP11- 
RP11- 

687F6 
699C17 
839G9 
837M2 
 
619L19a
397A16a
214L13a
450M22a
822F4’
859C21 
383D22 
700H19 
660C14 
248C13 
837J4 
275K5 

 
Accession nr of 
the BAC 
 
AP002391.1 
AP002393.1 
AP001910.2 
AC091111.4 
 
AC018994.7 
AC022031.8 
AC027584.4 
AC016165.11 
AC090758.2 
AC090408.2 
AC012301.5 
AC090296.2 
AP001772.2 
AC084350.1 
AP002417 
AC022724.8 

StSG46608 
WI-19692 
SHGC-58160 
StSG47676 
AFM357TD5, AFM191XCP9 
AFM357TD5 
RH123771 
SHGC-79995 
RH98615 
D18S69 
SHGC-7237 
SHCG-103952 
SHCG-103952 
D18S1245 
D18S1245 
WI-20204 
SHGC-154413 

RP11- 
762D8 
789F3 
817C16 
 

AP001487.3 
693L9 
 
 
 
 
 
 
LSI/IGH/BCL2b

SHGC-154413 
WI-5450, WI5827 
D18S1144, WI-5827 
WI2299, D18S1103 
 

Table 3. Proportion of clonal cells and composite karyotypes of the clones observed in multicolour FISH of blood samples and specified with G-banding 

Patient  Diagnosis  Proportion of 

clonal cells 
 
10/10  (100%) 

 
20/22  (91%) 

  
  SS 

 
11/11  (100%) 

 
  SS 

 
30/39  (77%) 

 
  SS 

 
16/24  (67%) 

 
3/45  (6.7%) 

 
5/24  (20.8%) 

 
2/70 (2,9%) 

 
 
 
 
 
2/25  (8.0%) 

 
 
 
 
0/54 (0%) 

 
0/43  (0.0%) 

Composite karyotypea
69-73,XY,-X[10],der(Y)t(Y;8)(?;?)[10], der(1)t(1;16)(q32;?)[10], 
+2[4],der(2)t(2;17)(p?21;q?21)[9], +3[7],der(4)t(4;1)(?;?)[10], 
der(5)t(4;5)(q26 or 28;?q21)x1-2[10],-7[10],+8[2],-10[9], 
der(12)t(12;18)(q?22;p11)x2[10], 
der(14)t(5;7;14)(q?13;q?11q36;p11)x2[10],   
der(16)t(1;16)(q32;p13),der(16)t(1;16)(?;?p)[10],-17[7], 
der(18)t(12;18)(?;p?)x1-2[10],+19[10],+22[9][cp10] 
 
36-98,X,-Y[17],der(1)t(1;9)(1pter->?1q11.1::9?->9?)x1-2[20],+5[8], 
del(5)(q21)x2-4[20],+7[9],+7,+7[3], 
del(7)(q?32)[8],ins(7;17)(p14;q25q12)[2],+8[18], 
del(8)(q?)[2],+9[16],der(9)t(1;9)(q10;?q10)del(1)(q?)x1-4[20], 
der(9)t(1;9)(q?->?::q11.1->pter)x1-2[7],+10[7],   
del(10)(p11 or 12)x1-2[18],del(12)(q?2)[13],-14[3],-17[3],i(17)(q10)[7], 
ider(17)t(7;17)(?;q?25)[5], der(17)t(10;17)(?;p?11.2)[2],+21[6],  
-22[3][cp19] 
 
 
44-91,XY,der(1)t(1;22)(q?42;?)[2], 
der(1)t(1;10)(p?34;?)t(1;22)(q?42;?)[9], 
der(1)t(1;11)(q21;p?14)[3], der(1)t(1;11)(q21;p?14)t(10;11)(?;p15)[9], 
der(3)t(3;5)(q25;q?15)[10],der(3)t(3;6)(q25;q22)[11], 
der(5)t(5;7)(q?15;q?)[11],del(6)(q2)[3], 
der(6)t(1;6)(6pter->6q22::1q21->1q23)[6], 
del(7)(q31)[10],der(7)t(7;10)(?q31;?)[10],+8[11], 
der(8)t(8;17)(?p1;?q1)[11],del(9)(q13)[11],-10[8], 
der(10)t(10;11)(?;?)t(10;17)(?;?)x1-2[10], 
der(11)t(1;11)(q24;p14)[11],t(12;18)(q15or21;q21)[11], 
del(15)(q1~21)[11],der(16)t(16;20)(q?;?)[11], 
],-17[11],der(17)t(7;17)(q?;q?),der(20)t(X;20)(?;?)[11], 
der(20)t(16;20)(?;?)[11][cp11] 
 
 
44-46,XX[4]X[7],t(X;3)(q12;p11)[6], 
der(2)t(10;2;10;2;10;13;14;13;14)[30],t(2;11)(q21;q11)[8], 
der(4)t(4;13)(q22;?)t(4;13)(q31;?)[30],+7[11], 
+del(8)(q22)[2],del(9)(q11)[3],der(10)t(8;10)[5],-13[7], 
der(13)t(2;13)[10],i(17)(q10)[12],der(17)t(X;17)(?p;p?11.2)[7], 
der(18)t(12;18)(?;?p)t(12;22)(?;?)[30], 
der(19)t(19;21)(p13;q11)[30],-21[30][cp30] 
 
 
39-48, XY[13], der(2)t(2;13)(p?21;?)[10], 
der(2)t(1;2)(?;q?35)t(2;13)(p16or21;q?)[3], 
der(3)t(3;9)(p21;p13)x1-2[14], 
der(4)t(4;12)(q31;?)[14],-5[3],del(8)(q?)[2],-9[12],-10[10], 
der(12)t(10;12)(?;q21.3 or q22)[13],-13[15], 
der(15)t(1;15)(?;p11.1)[9],der(16)t(10;16)(?;q24)[2], 
del(17)(p?)[9],-18[5],del(18)(p?)[3], 
der(19)t(15;19)(?;p13.3)[3],-20[3],-22[2][cp16] 
 
 
86-92,XXYY,t(2;6)(q33;q24 or 25)[3], 
der(2)t(2;6)(q33;q24 or 25)[3],-11[3] 
 
 
30-45,XY,-12[5] 

 
46,XY,dup(18)(q?;q?)[2] 

 
 
 
 
 
46,XY,del(9)(q11.1)[2] 

 

 

Special remarks  
der(12) specified with locus specific probes as  
der(12)del(12)(q15q15)(q?21q24)t(12;18) 
(q24;p11.3).  
Other breakpoints specified with G-banding. 

 
del(12) specified with locus specific probes as 
del(12)(q12q21) 

 
t(12;18) specified with locus specific probes as 
t(12;18)(q21;q21). 
Other breakpoints specified with G-banding. 
Additionally, one cell with der(10)t(11;10)(?;?), 

 
Breakpoints specified partly with G-banding 

 
Additionally, one cell with 
der(12)t(10;12)(?;q21.3 or  
22)t(10:12)(?;?)t(10;12) (?;?) and one other cell 
with del(12)(q12q21) 
One cell with sex chromosomes XXXY, two cells 
with -Y 

 
Two of the clonal cells showed -12 

 
 
 
 
 
Additionally 1 cell with karyotype 51X,i(Y)(q), 
+der(3),+del(5)(p11.1),+?del(12)(q21q24.1). 
iYq observed previously in G-banding as a clonal 
abnormality. 
 
 
 
Nonclonal aberrations of chromosome 12 
In previous G-banded blood samples three differ-
ent and one sideline clone, which 
diasappeared before the present sample10. 
 
 
Nonclonal aberrations of chromosome 12 
 
 

 
  1 
   

 
  2 
 

 
  3 
 

 
  4 
 

 
  5 
 

 
  6 
 
  
  7 
 
 
  8 
 
 
   
 
 
 
9 
 
 
 
 
 
10 
 
 
11 
 
 
12 
 

 
  SS 

 
  SS 

 
  SS 
 
 
  SS 

 
  MF 

 
   
 
 
 
MF 

 
   
 
 
  MF 

 
  MF 

 
  MF 

 
7/50  (14.0%) 

 
46-49,XX,+10[7],del(10)(p?11.2)(q?11.2)[7] 

 
Nonclonal aberrations of chromosome 12 
TCR beta analysis showed different TCR clones  
In skin and blood52

________________________________________________________________________________________________________________________ 

aISCN199512. For clonality of whole extra chromosomes, 3 cells required 7,12.Derivative chromosomes originating from      
more than four chromosomes have been presented as a chromosome list. 

 
Figure Legends 
 
Figure 7. Breakpoint of translocation (12;18)(q15or21;q21) and deletions of 12q in SS (cases 1 and 
2) were specified with part of the YAC contig 12.4. PCR confirmations of the localisation of the re-
spective YACs are indicated with symbols below. Approximation region 12q15 to 12q21 is marked 
with grey in the chromosome 12 ideogram (NCBI), with an approximation of the distal end of 12q21.1 
with an asterisk. Additionally, other YACs outside this region were studied:  893A3 (12q12, contig 
12.1,WI-1851;  850H3, 765B4, 12q13, contig 12.4, markers D12S72 and AFMB303XC1, respectively, 
patient 2), 803C2, 745A10   (12q14-q15, contig 12.4, markers WI-3072 and D12S313, respectively;  
Schoenmakers et al., Genomics 29: 665-678, 1995), 939H2 and 825G7 (cases 1 and 3; Schoenmakers et 
al., Genomics 29: 665-678, 1995),  817H10, 829B5, 896H8, 823E12, 948E9 (12q22-12q23, contig 12.5, 
markers CHLC.GATA69F06, D12S318, D12S338, D12S78;  Renault et al., Genomics 30: 81-83, 1995).  
For 12q24, PACS RP3-443K8, RP3-462E4, RP1-315L5 and BAC RP11-144J4 were used (AC005907, 
AC003029.3, AC002395.1, AC079406.6, respectively 
 
 
Figure 8. NAV3 is expressed in human astrocytes and normal human T-cells by RT-PCR. Lanes 
from left to right:  CCF astrocyte cells, whole skin lesion biopsy of a patient with CD30+ CTCL, whole 
skin lesion biopsy of case 15, and normal human blood T-cells stimulated with PHA. 
 
Figure 9. NAV3-silenced, GFP-expressing Jurkat (pLL3.7siRNA4) cells showed (a) a lowered ex-
pression of NAV3 compared with those infected with empty vector (b), and (c to f) a stronger ex-
pression of IL-2 protein as compared to non-infected cells or cells infected with the empty vector 
(pLL3.7 ) Cells infected with a) pLL3.7siRNA4 (GFP, green; NAV3, red), b) empty vector pLL3.7 
(GFP, green; NAV3, red ), c) pLL3.7siRNA4 (GFP,green, IL-2, red), d) same cell as in c) shows IL-2 
expression, white signal (IL-2, Alexa-594, shown in black-and-white by specific filter), e) cells infected 
with empty vector pLL3.7 (GFP, green; IL-2 red), f) same cells weakly expressing IL-2, white (IL-2, 
Alexa-594, shown in black-and-white by specific filter). 
 
 
Supplementary data for methods  
 
BACs used for the study of 18p. Following BACs (Research Genetics) were used for 18p11.3: RP11-
683l23 (AP001005.5), RP11-705O1 (AP000845.4), RP11-683J11 (AP000900.3), RP11-720L2 
(AP000915.5), RP11-778P8 (AC021474.3), and for 18p11.2, RP11-771B1 (AP000876.2). 
 
Locus-specific FISH. Probes were labeled with FITC (Fluorescein-12-dUTP, NEN Life Science 
Products, Inc, Boston MA USA), Alexa 488®, Alexa 594® (both Molecular probes, Leiden, The 
Netherlands), biotin-14dATP (Gibco Invitrogen, Rockville, MD, USA) or digoxigenin-11-dUTP 
(Roche, Mannheim, Germany) using nick translation. The biotin-labeled probes were detected with one 
or two layers of avidin-Cy3 (ExtrAvidin-Cy3 conjugate, Sigma-Aldrich, St Louis, Missouri, USA) or 
avidin-FITC (Vector Laboratories, Burlingame, CA, USA). The digoxigenin-labeled probes were de-
tected either with sheep anti-digoxigenin antibody (Roche, Mannheim, Germany) followed by donkey 
anti-sheep antibody labeled with FITC (Jackson West Grove, Pennsylvania, USA), or by sheep anti-
digoxigenin-rhodamine antibody (Roche, Mannheim). 
 
 
NAV3-expression. For NAV3 expression by reverse transcriptase-PCR the cDNA was synthesized  
with Revert Aid TM First Strand cDNA Synthesis Kit (Fermentas, St.Leon-Rot, Germany), and ampli-
fied with Nav3A-EcoF ( 5´-TTT GAA TTC TCT TCA GGT GTA AAT GGT AAC GTG-3’) and 
Nav3A-SalR (5’-TTT GTC GAC GAT CCT TCT CTT CTT TGA CTG GTT-3’) primer pair, in 40 cy-
cles of PCR (130sec 94(cid:31)C, 30sec 58(cid:31)C , 30sec 72(cid:31)C, 2 min 72(cid:31)C). The amplicon, 565 bp, was visu-
alized in 1.5 % agarose gel. 

  5´-ATC  CAT  GGA  GCT  CAG  CAA  CTC  -3´and 

 
For the real time quantitative RT-PCR total RNAs were first reverse transcribed as described above. To 
prepare standard curves serial dilutions of cDNA from SH-SY5Y cells were made. In the PCR reaction 
following  primers  were  used: 
  5’- 
TTGGCTGCTTCTTGGAGTTT-3´ were used. The reactions were performed in LightCyclerTM appara-
tus using an LC Fast Start DNA SYBR Green 1 kit (Roche Diagnostics, Mannheim, Germany). Briefly, 
the DNA was denatured in 95(cid:31)C  for 10 minutes, then 50 cycles of denaturation, annealing, and po-
lymerization were run in 95(cid:31)C, 58(cid:31)C, and 72(cid:31)C for 10, 5 and 8 seconds, followed by melting curve 
analysis  according  to  the  manufacturer's  guidelines.  After  arithmetic  background  adjustment,  the  fit 
point method was used to determine the crossing-point value as previously described (Linja et al, Clin 
Cancer Res 10: 1032-1040, 2004).  For the normalization of the expression levels, the expression of 
TATA-binding protein (TBP) was measured as described (Linja et al., Clin Cancer Res 10: 1032-1040, 
2004). The relative expression level was obtained by dividing the values for NAV3 with the TBP value.  
In addition to the melting curve analysis, the PCR products were run in 1.5% agarose gel electrophore-
sis to ensure that a right size but not other products were amplified in the reaction.  
 
Immunofluorescence. Anti NAV3 was detected with Alexa Fluor™594 goat anti-rabbit IgG conjugate 
(Molecular Probes, Leiden, Netherlands).Anti-GFP mouse or rabbit antibodies were detected with 
biotinylated horse anti-mouse or goat anti-rabbit antibodies (both Vector Laboratories, Burlingame, CA, 
USA), followed by avidin-FITC. In other immunofluorescence analyses, donkey anti-mouse, anti-rabbit 
or anti-goat, all conjugated with Rhodamine Rex X (Jackson Immuno Research), and goat anti–mouse 
or anti-rabbit or donkey anti-goat antibodies, all conjugated with Alexa 594 (Molecular Probes), were 
used. 
 
 
 
 

